These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 9170891)

  • 21. Lipoprotein (a) and coronary heart disease.
    Maher VM; Brown BG
    Curr Opin Lipidol; 1995 Aug; 6(4):229-35. PubMed ID: 7670752
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The smoking gun of cardiovascular diseases? The great interest in Lp(a)-lipoprotein].
    Dahlén GH
    Lakartidningen; 1993 Jan; 90(4):259-62. PubMed ID: 8433604
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipoprotein(a): structural implications for pathophysiology.
    Koschinsky ML; Marcovina SM
    Int J Clin Lab Res; 1997; 27(1):14-23. PubMed ID: 9144023
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolic factors clustering, lipoprotein cholesterol, apolipoprotein B, lipoprotein (a) and apolipoprotein E phenotypes in premature coronary artery disease in French Canadians.
    Weber M; McNicoll S; Marcil M; Connelly P; Lussier-Cacan S; Davignon J; Latour Y; Genest J
    Can J Cardiol; 1997 Mar; 13(3):253-60. PubMed ID: 9117913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Lipoprotein (a) - an independent risk factor in atherosclerosis].
    Ezhov MV; Liakishev AA; Pokrovskiĭ SN
    Ter Arkh; 2001; 73(9):76-82. PubMed ID: 11642088
    [No Abstract]   [Full Text] [Related]  

  • 26. Lipoprotein(a) concentration and apolipoprotein(a) size: A synergistic role in advanced atherosclerosis?
    Marcovina SM; Koschinsky ML
    Circulation; 1999 Sep; 100(11):1151-3. PubMed ID: 10484533
    [No Abstract]   [Full Text] [Related]  

  • 27. [The pharmacological effects of certain compounds on lipoprotein(a)].
    Monte G; Mezdour H
    Recenti Prog Med; 1993 Dec; 84(12):855-63. PubMed ID: 8108601
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk factors: Lipoprotein(a) and coronary disease-moving closer to causality.
    Danesh J; Erqou S
    Nat Rev Cardiol; 2009 Sep; 6(9):565-7. PubMed ID: 19696776
    [No Abstract]   [Full Text] [Related]  

  • 29. Effect of race on lipoprotein profile.
    Thé TG; Downing JW
    J Pediatr; 1994 Dec; 125(6 Pt 1):1014-5. PubMed ID: 7996348
    [No Abstract]   [Full Text] [Related]  

  • 30. Lipoprotein(a) and its role in occlusive vascular disease.
    Tennant M; McGeachie JK
    Ann R Coll Surg Engl; 1993 Jan; 75(1):3-7. PubMed ID: 8422141
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Lipoprotein(a). Its importance as an additional atherosclerosis marker].
    Campos E
    Acta Med Port; 1997 Jan; 10(1):87-93. PubMed ID: 9245184
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lipoprotein(a), atherosclerosis, and apolipoprotein(a) gene polymorphism.
    Pati U; Pati N
    Mol Genet Metab; 2000; 71(1-2):87-92. PubMed ID: 11001801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Arterial thrombosis: putative role of lipoprotein(a).
    El LT; Brown BM
    Crit Care Nurs Clin North Am; 1993 Sep; 5(3):435-43. PubMed ID: 8217039
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic variants in Lp(a) lipoprotein and coronary disease.
    Jaeger BR; Labarrere CA
    N Engl J Med; 2010 Mar; 362(12):1146-7; author reply 1147-8. PubMed ID: 20344827
    [No Abstract]   [Full Text] [Related]  

  • 35. [Lipoprotein(a) and Apo-A isoforms in patients with intermittent claudication].
    Britareva VV; Afanas'eva OI; Dobrovol'skiĭ AB; Ezhov MV; Titaeva EV; Karpov IuA; Pokrovskiĭ SN
    Ter Arkh; 2002; 74(12):49-52. PubMed ID: 12577841
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between plasma lipoprotein (a), apolipoprotein (a) phenotypes, and other coronary heart disease risk factors in a Melbourne South Asian population.
    Xiong ZW; Wahlqvist ML; Ibiebele TI; Biegler BM; Balazs ND; Xiong DW; Lim YL
    Clin Biochem; 2004 Apr; 37(4):305-11. PubMed ID: 15003733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease.
    Tsimikas S; Brilakis ES; Miller ER; McConnell JP; Lennon RJ; Kornman KS; Witztum JL; Berger PB
    N Engl J Med; 2005 Jul; 353(1):46-57. PubMed ID: 16000355
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low-density lipoprotein size and subclasses are markers of clinically apparent and non-apparent atherosclerosis in type 2 diabetes.
    Berneis K; Jeanneret C; Muser J; Felix B; Miserez AR
    Metabolism; 2005 Feb; 54(2):227-34. PubMed ID: 15690318
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of serum lipoprotein(a) levels and apolipoprotein(a) size polymorphism with target-organ damage in arterial hypertension.
    Sechi LA; Kronenberg F; De Carli S; Falleti E; Zingaro L; Catena C; Utermann G; Bartoli E
    JAMA; 1997 Jun; 277(21):1689-95. PubMed ID: 9169895
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipoprotein Lp(a) excess and coronary heart disease.
    Stein JH; Rosenson RS
    Arch Intern Med; 1997 Jun; 157(11):1170-6. PubMed ID: 9183227
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.